Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2016-06-24 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-06-24 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated June 22, 2016. It reports the submission of matters to a vote of security holders at the company's 2016 Annual Meeting of Stockholders, including election of directors and ratification of the independent auditor. The content focuses on the official results of shareholder votes at the Annual Meeting. The document length is 3447 characters, which is relatively short and consistent with a voting results announcement rather than a full report. The key phrase 'Submission of Matters to a Vote of Security Holders' and the detailed vote counts confirm this is a Declaration of Voting Results. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-06-24 English
Regulatory Filings 2016
Regulatory Filings
2016-06-02 English
Regulatory Filings 2016
Regulatory Filings Classification · 100% confidence The document is a letter from Cidara Therapeutics, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and discusses procedural acknowledgments related to the filing's effectiveness. There is no financial data, report content, or detailed disclosures typical of an Annual Report, Interim Report, or other substantive filings. The document is short (2044 characters) and serves as a formal request related to a regulatory filing process rather than the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and procedural correspondence with the SEC that do not fit other categories.
2016-05-27 English
Regulatory Filings 2016
Regulatory Filings
2016-05-26 English
FORM 4 SUBMISSION
Director's Dealing
2016-05-23 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.